Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Lancet. Oncology|October 26, 2007
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyOlivier Rixe, Ronald M Bukowski, M Dror Michaelson, et al.
Lancet (London, England)|June 3, 2008
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II studyJean-Philippe Spano, Catherine Chodkiewicz, Joan Maurel, et al.
Clinical Colorectal Cancer|November 6, 2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II studyJohanna C Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, et al.
The Lancet. Oncology|April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialRobert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumorsBrian I Rini, Joan H Schiller, John P Fruehauf, et al.
Cancer|April 23, 2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 studyJeffrey R Infante, Tony R Reid, Allen L Cohn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyEzra E W Cohen, Lee S Rosen, Everett E Vokes, et al.
Cancer|May 22, 2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessmentsLaura D Locati, Lisa Licitra, Laura Agate, et al.
The Lancet. Oncology|February 11, 2011
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L Kindler, Tatsuya Ioka, Dirk J Richel, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Pageof 6